Astrid Zobel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Astrid Zobel has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Wolfgang Maier
Department of Psychiatry and Psychotherapy, University of Bonn , Germany
5 shared publicationsUte Pfeiffer
Department of Psychiatry and Psychotherapy, University of Bonn , Germany
4 shared publicationsAnna Schuhmacher
Department of Psychiatry and Psychotherapy, University of Bonn, Germany
2 shared publicationsMartin Metten
Department of Psychiatry, University of Bonn , Germany
2 shared publications- Michael Wagner
Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany
2 shared publications Nikolaus Freymann
2 shared publications
Latest Publications
- Open Access
- 12 August 2010
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 14 (02) , 237-245
PCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder
Variant rs2522833 of the Piccolo-encoding gene PCLO has recently been found to be associated with major depressive disorder (MDD). PCLO encodes a pre
- 12 August 2010
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 14 (02) , 237-245
Open AccessPCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder
Variant rs2522833 of the Piccolo-encoding gene PCLO has recently been found to be associated with major depressive disorder (MDD). PCLO encodes a pre
- Open Access
- 5 January 2010
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 13 (05) , 649-660
DNA sequence variants of the FKBP5 gene are associated with unipolar depression
FKBP5 is a glucocorticoid receptor-regulating co-chaperone of hsp-90 and, therefore, is suggested to play a role in the regulation of the hypothalami
- 5 January 2010
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 13 (05) , 649-660
Open AccessDNA sequence variants of the FKBP5 gene are associated with unipolar depression
FKBP5 is a glucocorticoid receptor-regulating co-chaperone of hsp-90 and, therefore, is suggested to play a role in the regulation of the hypothalami
- Open Access
- 15 October 2009
- Published by Springer Nature in BMC Medicine
- Vol. 7 (1) , 60
Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
Suicidal thoughts and behaviours during antidepressant treatment, especially during the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present study is to investigate the course and predictors of emergence and worsening of suicidal ideation during tricyclic antidepressant and serotonin reuptake inhibitor treatment. In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks. The suicidality items of three standard measures were integrated in a suicidal ideation score. Increases in this score were classified as treatment emergent suicidal ideation (TESI) or treatment worsening suicidal ideation (TWOSI) according to the absence or presence of suicidal ideation at baseline. Suicidal ideation decreased during antidepressant treatment. Rates of TESI and TWOSI peaked in the fifth week. Severity of depression predicted TESI and TWOSI. In men, nortriptyline was associated with a 9.8-fold and 2.4-fold increase in TESI and TWOSI compared to escitalopram, respectively. Retirement and history of suicide attempts predicted TWOSI. Increases in suicidal ideation were associated with depression severity and decreased during antidepressant treatment. In men, treatment with escitalopram is associated with lower risk of suicidal ideation compared to nortriptyline. Clinicians should remain alert to suicidal ideation beyond the initial weeks of antidepressant treatment. EudraCT (No.2004-001723-38) and ISRCTN (No. 03693000).
- 15 October 2009
- Published by Springer Nature in BMC Medicine
- Vol. 7 (1) , 60
Open AccessSuicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
Suicidal thoughts and behaviours during antidepressant treatment, especially during the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present study is to investigate the course and predictors of emergence and worsening of suicidal ideation during tricyclic antidepressant and serotonin reuptake inhibitor treatment. In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks. The suicidality items of three standard measures were integrated in a suicidal ideation score. Increases in this score were classified as treatment emergent suicidal ideation (TESI) or treatment worsening suicidal ideation (TWOSI) according to the absence or presence of suicidal ideation at baseline. Suicidal ideation decreased during antidepressant treatment. Rates of TESI and TWOSI peaked in the fifth week. Severity of depression predicted TESI and TWOSI. In men, nortriptyline was associated with a 9.8-fold and 2.4-fold increase in TESI and TWOSI compared to escitalopram, respectively. Retirement and history of suicide attempts predicted TWOSI. Increases in suicidal ideation were associated with depression severity and decreased during antidepressant treatment. In men, treatment with escitalopram is associated with lower risk of suicidal ideation compared to nortriptyline. Clinicians should remain alert to suicidal ideation beyond the initial weeks of antidepressant treatment. EudraCT (No.2004-001723-38) and ISRCTN (No. 03693000).
- 1 August 2005
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 139 (3) , 165-179
Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: An exploratory approach
- 1 August 2005
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 139 (3) , 165-179
Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: An exploratory approach
- 1 October 2004
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 254 (5) , 303-311
Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy
Excess comorbidity between depression and epilepsy proposes common pathophysiological patterns in both disorders. Neuroendocrine abnormalities were often observed in depression as well as in epilepsy. Lack of inhibitory control of the hypothalamic pituitary adrenocortical (HPA) system is a core feature of depression; main relay stations of this system are located in the amygdala and hippocampus, which are key regions for both disorders. Therefore we explored the feedback mechanism of the HPA system in epilepsy. In order to control for the impact of depression we focused on epilepsies without depression. We compared patients with epilepsy (subdivided by medication with or without hepatic enzyme inducing antiepileptic medication) with 16 healthy controls and 16 patients with unipolar major depression but without epilepsy. We observed a lack of inhibitory control of the HPA system in patients with epilepsy, also in the absence of enzyme inducing medication. An impact of the temporal lobe location of the epileptic focus could not be observed. Thus, epilepsies share with depression the deficiencies in the feedback mechanism of the HPA system, proposing common pathophysiological features of up to now unknown nature.
- 1 October 2004
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 254 (5) , 303-311
Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy
Excess comorbidity between depression and epilepsy proposes common pathophysiological patterns in both disorders. Neuroendocrine abnormalities were often observed in depression as well as in epilepsy. Lack of inhibitory control of the hypothalamic pituitary adrenocortical (HPA) system is a core feature of depression; main relay stations of this system are located in the amygdala and hippocampus, which are key regions for both disorders. Therefore we explored the feedback mechanism of the HPA system in epilepsy. In order to control for the impact of depression we focused on epilepsies without depression. We compared patients with epilepsy (subdivided by medication with or without hepatic enzyme inducing antiepileptic medication) with 16 healthy controls and 16 patients with unipolar major depression but without epilepsy. We observed a lack of inhibitory control of the HPA system in patients with epilepsy, also in the absence of enzyme inducing medication. An impact of the temporal lobe location of the epileptic focus could not be observed. Thus, epilepsies share with depression the deficiencies in the feedback mechanism of the HPA system, proposing common pathophysiological features of up to now unknown nature.
- 1 July 2004
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 38 (4) , 377-383
Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment
- 1 July 2004
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 38 (4) , 377-383
Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment
- 1 March 2004
- Published by Springer Nature in Der Nervenarzt
- Vol. 75 (3) , 205-214
Endophänotypen—ein neues Konzept zur biologischen Charakterisierung psychischer Störungen
Das Konzept "Endophänotyp" hat in der psychiatrischen Genetik derzeit eine hohe Popularität. Die gegenwärtigen Schwierigkeiten bei der Suche nach Suszeptibilitätsgenen für komplexe Erkrankungen wird auf die ätiologische Heterogenität des klinischen, psychopathologisch definierten Krankheitsphänotyps zurückgeführt. Neurobiologische Krankheitskorrelate, die stabil über die Zeit sind und genetisch beeinflusst sind, werden statt dessen als erfolgversprechendere Zielphänotypen betrachtet, da sie von den unmittelbaren Geneffekten direkter beeinflusst sind und vermutlich einer weniger komplexen genetischen Determination unterliegen als der Krankheitsphänotyp. Die Endophänotypstrategie war in anderen Bereichen der Medizin bei komplexen Erkrankungen, aber auch bei Alkoholismus und spät beginnender Alzheimer-Erkrankung, erfolgreich. Bei der Schizophrenie ist eine Serie von Endophänotypen für die molekulargenetische Untersuchung vorgeschlagen worden. Daneben kann das Konzept des Endophänotyps aber auch eine Grundlage für die biologische Klassifikation psychischer Störungen bieten. In the field of psychiatric genetics, the concept of endophenotypes is presently receiving high popularity. Current difficulties in the search for susceptibility genes of complex diseases have been attributed to the etiological heterogeneity of the clinical, psychopathologically defined phenotype of the disease. Neurobiological correlates of the disease which are genetically influenced and stable over time are considered to be more promising targets of phenotypes. They are more directly influenced by gene effects and presumably defined by a genetic determination which is less complex than the phenotype of the disorder. The endophenotype strategy has already been successful in complex disorders of other areas in medicine, including alcoholism and late-onset Alzheimer's disease. For schizophrenia, a series of endophenotypes for molecular/genetic investigation has been suggested, but the concept "endophenotype" also provides a basis for biological classification of mental disorders.
- 1 March 2004
- Published by Springer Nature in Der Nervenarzt
- Vol. 75 (3) , 205-214
Endophänotypen—ein neues Konzept zur biologischen Charakterisierung psychischer Störungen
Das Konzept "Endophänotyp" hat in der psychiatrischen Genetik derzeit eine hohe Popularität. Die gegenwärtigen Schwierigkeiten bei der Suche nach Suszeptibilitätsgenen für komplexe Erkrankungen wird auf die ätiologische Heterogenität des klinischen, psychopathologisch definierten Krankheitsphänotyps zurückgeführt. Neurobiologische Krankheitskorrelate, die stabil über die Zeit sind und genetisch beeinflusst sind, werden statt dessen als erfolgversprechendere Zielphänotypen betrachtet, da sie von den unmittelbaren Geneffekten direkter beeinflusst sind und vermutlich einer weniger komplexen genetischen Determination unterliegen als der Krankheitsphänotyp. Die Endophänotypstrategie war in anderen Bereichen der Medizin bei komplexen Erkrankungen, aber auch bei Alkoholismus und spät beginnender Alzheimer-Erkrankung, erfolgreich. Bei der Schizophrenie ist eine Serie von Endophänotypen für die molekulargenetische Untersuchung vorgeschlagen worden. Daneben kann das Konzept des Endophänotyps aber auch eine Grundlage für die biologische Klassifikation psychischer Störungen bieten. In the field of psychiatric genetics, the concept of endophenotypes is presently receiving high popularity. Current difficulties in the search for susceptibility genes of complex diseases have been attributed to the etiological heterogeneity of the clinical, psychopathologically defined phenotype of the disease. Neurobiological correlates of the disease which are genetically influenced and stable over time are considered to be more promising targets of phenotypes. They are more directly influenced by gene effects and presumably defined by a genetic determination which is less complex than the phenotype of the disorder. The endophenotype strategy has already been successful in complex disorders of other areas in medicine, including alcoholism and late-onset Alzheimer's disease. For schizophrenia, a series of endophenotypes for molecular/genetic investigation has been suggested, but the concept "endophenotype" also provides a basis for biological classification of mental disorders.